Caplin Point Laboratories announces the successful completion of an inspection by INVIMA-Colombia at its injectables facility in Puducherry. The inspection, conducted between December 8th and 12th, 2025, demonstrates the company’s commitment to delivering high-quality medicines to Latin America. This achievement marks a significant milestone in Caplin Point’s strategy for expansion in the Latin American market.
Puducherry Facility Cleared
Caplin Point Laboratories has announced that INVIMA-Colombia conducted an inspection of its injectables manufacturing facility located in Puducherry. The inspection, which took place between December 8th and 12th, 2025, has been successfully completed.
Significance for Latin American Expansion
According to Chairman Mr. C.C. Paarthipan, the successful completion of the INVIMA inspection at the Puducherry facility reinforces Caplin Point’s commitment to expanding its reach in Latin America. The company aims to deliver high-quality, affordable medicines to patients in the region.
This development is also seen as a crucial milestone in the company’s product strategy to expand in the larger Latin American market for specialty injectable products, complementing its existing INVIMA approved Softgel section at the same facility.
Source: BSE
